Breaking AI & Tech News Analyzed

For the first time, thousands of cancer patients from Black and minority ethnic backgrounds will benefit from an enhanced genetic test offered by the NHS. The new screening expands the panel of DPYD gene variants from four to five, directly addressing a long‑standing bias that left non‑white patients vulnerable to dangerous chemotherapy side‑effects. In England, patients slated for chemotherapy undergo a genetic check that can guide dose adjustments and mitigate adverse reactions such as mouth sores, hair loss, nausea, fatigue, and, in severe cases, death. Up to 40% of the 38,000 individuals receiving fluoropyrimidine‑based chemotherapy each year experience a harmful drug reaction. Previously, the test only targeted four DPYD variants common in people of European descent, meaning many Black patients received inaccurate “all‑clear” results. The addition of a fifth variant—more prevalent among African, Caribbean and other minority groups—means clinicians can now identify patients at risk who were previously missed. Since its rollout at Manchester University NHS Foundation Trust last September, three minority‑ethnic patients have had their initial chemotherapy doses adjusted, lowering their chance of a potentially fatal reaction. Dr Veline L’Esperance, senior clinical adviser at the NHS Race and Health Observatory, called the change “tangible results for patients who have historically been left behind.” She emphasized that the update shifts the discussion on ethnic health inequality from rhetoric to actionable care. Prof Habib Naqvi, chief executive of the NHS Race and Health Observatory, described the development as a “groundbreaking outcome” for chemotherapy safety, while noting that ethnic minorities remain under‑represented in genomic research and biobanks. He warned that broader inclusion is essential for the promised benefits of precision medicine to reach all communities. Prof Dame Sue Hill, chief scientific officer for NHS England, highlighted the significance of discovering the fifth variant: “Personalising chemotherapy based on genetics can save lives and reduce harmful side‑effects, especially for patients of African ancestry.” She added that the North West NHS Genomic Medicine Service has already demonstrated the practical impact of this approach. These steps come amid broader evidence that minority patients in the UK face longer diagnostic waits, more GP visits before a cancer diagnosis, and lower perceived support during treatment. The expanded DPYD test represents a concrete effort to close those gaps and ensure equitable, science‑driven care for all cancer patients.

England and Spain meet again on Tuesday night in front of more than 70,000 at Wembley in the Women's World Cup 2027 qualifiers. This match comes eight-and-a-half months after they faced off in the Euro 2025 final, which England won.Spain has undergone significant changes since then, with a new head coach, Sonia Bermúdez, and a crop of emerging young players. Despite these changes, they remain unbeaten since the Euros with five wins and a draw in six matches. Bermúdez has already led them to the Nations League title.The visitors have a number of talented young players, including Fiamma Benítez, the 21-year-old Atlético Madrid midfielder, who has made a strong impact with seven goal contributions in the Champions League this season. Another player to watch is Vicky López, the Barcelona winger, who has become a regular starter.England head coach Sarina Wiegman believes that despite the changes, Spain's DNA remains the same: they want to have the ball and play dynamically. Wiegman noted that there might be some tweaks but the principle will be very similar.For England, Leah Williamson is an injury doubt due to a hamstring injury, but she has started training with her international teammates. Keira Walsh is set to win her 100th cap and Wiegman praised her vision and game understanding.England will have to make at least one change from the starting XI that beat Spain in Switzerland, with Ella Toone out injured. Jess Park is likely to start in her place.

Tottenham Hotspur have lost their captain Cristian Romero for the remainder of the 2025‑26 Premier League campaign after sustaining medial knee‑ligament damage in a clash with Sunderland striker Brian Brobbey. The injury, expected to require around eight weeks of rehabilitation, forces Romero off the pitch for the final six matches that will decide whether the club remains in the top flight.Romero left the Stadium of Light in tears after 70 minutes of a 1‑0 defeat, the goal coming from his own goalkeeper Antonín Kinský following the collision. The Argentine defender’s absence adds to an already extensive injury list that includes James Maddison, Dejan Kulusevski, Wilson Odobert and Mohammed Kudus. Goalkeeper Guglielmo Vicario is also sidelined after a hernia operation, leaving Kinský as the starter.Spurs sit 18th after a season that has seen them lose 16 league games and fail to register a domestic win in 2026. Manager Roberto De Zerbi admitted the blow could be “a big problem” but stressed the need for the squad to rally: “He’s a good guy, a top player, and we need him to finish the season and achieve our goal.”The incident also sparked a backlash against Brobbey, who was targeted with racist abuse on social media. Sunderland issued a statement pledging full support for the striker and confirming that the matter has been reported to the Premier League, relevant platforms and the police.With the relegation battle intensifying, Tottenham’s ability to replace Romero’s defensive leadership will be crucial as they fight to stay in the Premier League.

Euphoria's third season has been a long-awaited return, but unfortunately, it's absolutely not worth the wait. The show's creator, Sam Levinson, has taken a darker and more desperate approach, focusing on the characters' bleak lives and struggles with sex work, drugs, and trauma.The season picks up five years after the end of season two, with recovering addict Rue (Zendaya) drawn into the world of drug dealer Laurie (Martha Kelly). Her life as a mule between Mexico and the US is depicted in gritty and intense cinematic sequences, drawing on westerns and blaxploitation.Meanwhile, Cassie (Sydney Sweeney) is on the cusp of trad wifedom with toxic jock Nate (Jacob Elordi), but their relationship is marred by Nate's crumbling business and Cassie's OnlyFans content. The show's handling of her cam girl ambitions feels bafflingly dated and voyeuristic.The performances are mostly good, with standout performances from Zendaya, Sweeney, and Adewale Akinnuoye-Agbaje. However, the show's grim and humorless tone makes it feel like a chore to watch.Levinson's approach to exploring the devastating impact of synthetic opioids on ordinary Americans feels heavy-handed and desperate. The show's focus on brainrot bimbo-ism and male perversion also detracts from its once unapologetically queer heart.Overall, Euphoria season three is a disappointing and grubby addition to the series, feeling like a contractual obligation rather than a passion project.

Meta, the company behind Facebook and Instagram, is reportedly working on an AI version of its CEO, Mark Zuckerberg. This AI clone is being trained on Zuckerberg's mannerisms, tone, and public statements to allow employees to interact with a digital version of their boss.The rationale behind this project is to make Meta's 79,000 employees feel more connected to one of the most influential figures in Silicon Valley. The AI character will be developed using images and the voice of Zuckerberg, with the CEO reportedly taking part in the training process.This move is part of Meta's broader effort to integrate AI into its business operations. The company aims to use AI to lower costs and accelerate work pace. Zuckerberg has emphasized the importance of efficiency, stating that the goal is to 'get more done' by elevating individual contributors and flattening teams.The development of this AI character follows Meta's previous experiments with digital avatars. In 2022, Zuckerberg shared his own avatar in the metaverse, which received public criticism for its graphic quality. The company has since scaled back its metaverse vision, focusing on AI-generated 3D characters for everyday conversations.Meta's investment in AI is part of a larger strategy to remain competitive with tech rivals. The company is pouring billions of dollars into AI research to create 'superintelligence,' a system capable of performing any cognitive task far better than a human.

While the two‑week pause in the US‑Israel campaign against Iran remains uncertain, one constant is clear: Donald Trump lacks a concrete plan, but Benjamin Netanyahu does. The war’s stated aim – to cripple Iran’s state capacity – is only a stepping stone toward a larger vision of a Greater Israel. For Israel’s right‑wing, the phrase often evokes a purely territorial ambition: enlarging the land Israel claims. History shows this expansionist drive has repeatedly displaced Palestinians, a process that has accelerated dramatically in recent years. Since the war began, Israel has flattened Gaza, killing tens of thousands and reducing the civilian‑inhabitable area to roughly 12 % of its pre‑war size. In the West Bank, a wave of settlement expansion and property destruction rivals the scale of the 1967 conflict. Beyond the occupied territories, Israel has seized parts of Syria and is forging a de‑facto occupation zone in southern Lebanon, with ministers from Religious Zionism, Jewish Power and Likud openly demanding Israeli sovereignty there. Finance minister Bezalel Smotrich even called for an expansion “to Damascus,” and Netanyahu has publicly expressed a deep personal connection to this territorial vision. However, Greater Israel is as much a geopolitical and strategic construct as a land‑grab. Netanyahu’s ambition extends beyond occupying borders; he seeks a regional dominion built on new alliances and hard‑power dependencies. After the October 7 attacks and the ensuing Gaza devastation, Israel’s prospects for Arab‑state normalization stalled. Faced with a choice between a conciliatory approach and a zero‑sum rejection of a Palestinian future, Netanyahu chose the latter, aiming to eliminate Iran as a regional counterweight – a move that inevitably required massive US military involvement. Former Israeli security analysts note that, from the perspective of Sunni Gulf states, a weakened Iran would elevate Israel to the role of “dominant regional power.” Achieving this, according to the article, also means softening the Gulf Cooperation Council (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, UAE) and making them dependent on Israel for security and energy routes. The spill‑over of Iranian drone and missile attacks on GCC infrastructure is portrayed not as an accident but as a calculated element of Israel’s strategy. When the US‑Israel coalition struck Iranian energy sites, Iran retaliated against the Gulf, disrupting global oil flows through the Strait of Hormuz. Netanyahu seized the moment to propose “alternative routes” – oil and gas pipelines that would bypass Hormuz and Bab‑al‑Mandab, ending at Israeli Mediterranean ports. In a meeting with Indian Prime Minister Narendra Modi, Netanyahu outlined a “hexagon of alliances” linking India, Arab nations, African states, Greece, Cyprus and other Asian partners, positioning Israel as the central hub. Recent IDF strategy papers echo this, suggesting Israel could achieve “operational control” far beyond its borders without permanent occupation, likening the Middle East to a “jungle” where Israel would become the “queen.” Netanyahu now describes Israel not merely as a “regional superpower” but, in some contexts, as a “global superpower.” He promises the hexagonal alliance will confront a “radical Shia axis” and an “emerging radical Sunni axis,” with Turkey singled out as the next strategic threat. Dismissal of the Greater Israel rhetoric as wartime hyperbole would be misleading. The article warns that a permanent war‑oriented mindset permeates Israel’s political elite, security establishment and media, posing a risk of overreach and regional blowback. Containing this expansive vision may become one of the most pressing post‑war challenges for the Middle East.

Mid Wales Opera's OpenStages productions are undertaken with a missionary zeal, nurturing both local communities and up-and-coming singing talent. Their recent staging of Purcell's Dido and Aeneas, realized remarkably over a single intensive week of work, is a testament to this commitment.The opera, tailored by Purcell for the ladies of Josias Priest's boarding school in Chelsea in 1689, features a motley crew of amateurs forming a chorus portraying Carthaginian courtiers, followers of a witches' coven, and sailors. The young cast, some already launched on singing careers, delivered polished performances under the care of conductor Jonathan Lyness, particularly in their recitatives.Director Richard Studer's simple yet effective set design, featuring a central high pavilion on a raised dais against a cathedral backdrop, elegantly framed the action. The chorus, dressed in black with pale golden patches on their cheekbones, contrasted with the titular pair, Queen Dido and Aeneas, in standout white with elaborate golden facial adornments.Kathy Macaulay's portrayal of Dido conveyed vulnerability from the outset, while Alaw Grug Evans' expressive performance as Belinda added depth to the narrative. The production's inexorable progress towards Dido's final aria, When I am lain in earth, brought the tragedy full circle, underscored by the MWO string ensemble's lamenting mood.

Scientists at London's Institute of Cancer Research and the RCSI University of Medicine and Health Sciences in Dublin have announced a new AI-driven approach to identify how patients with advanced bowel cancer will respond to bevacizumab, a drug recently introduced by the NHS. The method uses PhenMap, an AI tool that integrates complex data on the genetic makeup of tumors, allowing researchers to track patterns of how different patients react to the drug. This development aims to spare potentially thousands of patients from being given drugs that would be ineffective in fighting their cancers. In the UK alone, nearly 10,000 cases of advanced bowel cancer are identified every year, with young adults seeing a particular rise in diagnoses. Bowel cancer has the second-highest mortality rate of any cancer, behind only lung cancer. While survival rates can be as high as 98% when caught early, the five-year survival rate for advanced bowel cancer can be as low as 10%. The study tracked 117 European bowel cancer patients who had been treated with chemotherapy and bevacizumab. Researchers identified a group of patients who all had the same gene mutation and were at a high risk of having negative reactions. The scientists behind the tests now hope to expand the number of patient samples and see if the results can be used in treatments for other types of cancer. Anguraj Sadanandam, a professor in stratification and precision medicine at the ICR, said: “Once bowel cancer spreads to other parts of the body, there are very few treatment options available for patients. It is therefore positive that patients can now access the targeted drug bevacizumab on the NHS. However, we know that the majority of patients won’t benefit from the drug, meaning thousands of people in England could be facing unpleasant side effects unnecessarily.” Sadanandam added that while the findings were encouraging, the tool would need to be tested on a larger cohort to be validated. “In future, I hope this approach will lead to a test that can be used by clinicians, to ensure patients receive personalised care that has the highest chance of working against their cancer.”

Rising energy costs stemming from the Iran war are set to deliver a sharp blow to British living standards, with the Resolution Foundation estimating that the average working‑age household could lose about £480 in income this year. Before the conflict began, the think‑tank projected a modest 0.9% rise in household earnings. Market‑driven energy price spikes have now pushed that forecast into a -0.6% decline, effectively turning a gain into a loss. Oil and gas markets have reacted dramatically: Brent crude has surged back above $100 per barrel (£74), while analysts such as JPMorgan Chase expect prices to stay elevated through the current quarter, with Goldman Sachs revising its Brent outlook to an average of $90 per barrel in Q2. For the poorest fifth of households, the outlook is equally grim. Expected income growth has been trimmed from 2.8% to 1.2%, despite a long‑overdue real‑terms increase in benefits for some low‑income families. Families with three or more children stand out as a relative bright spot. The abolition of the two‑child limit is projected to generate a 7.7% income boost for this group, contrasting with zero growth for poorer families with fewer children. Energy bills are also poised to climb this summer, erasing the £117 average savings households enjoyed after the regulator lowered the energy price cap in April, according to Jonathan Marshall, the foundation’s principal economist. In response, the Resolution Foundation is urging the UK government to fast‑track a social tariff before winter, aiming to shield the most vulnerable households from the worst of the price shock. James Smith, chief economist at the foundation, warned that “while hopes for sustained peace persist, the path of this conflict remains uncertain and energy prices stay well above pre‑war levels, meaning many households face a decline in purchasing power this year.” He added that “de‑escalation is welcome, but the damage to household finances is already largely done; the government should act now to prepare a social tariff that reaches households falling through the cracks this winter.”